Study participants whose slumber routines followed a clearer pattern of sleeping through the evening time and remaining awake throughout the day were less likely to have major clumps of amyloid protein within their brains, suggesting they were not as inclined to go on to develop Alzheimer's illness.
An analog that mimics mitochondrial protein called coenzyme Q10 (CoQ10) has been found to protect neuronal mitochondria from the damaging effects of protein aggregates seen in Alzheimer's disease.
The test has so far been trialled on two cohorts - comprising 252 Australian and 121 Japanese volunteers - and has successfully detected low levels of amyloid-beta fragments in the blood.
Koichi Tanaka, who won the Nobel Prize for Chemistry 16 years ago, is a member of the Shimadzu side of the project. "This does seem to be an important study", says James Hendrix, who was not involved in the new research and is director of Global Science Initiatives for the Alzheimer's Association, the largest nonprofit funder of Alzheimer's research. "However, determination of levels of Aßs in plasma is very hard due to several reasons". They found the amount of amyloid present in the blood correlated with the degree of cognitive problems. The researchers found these ratios to be predictive of brain amyloid buildup.
"It wasn't that the people in the study were sleep-deprived", lead study author Erik Musiek said in a press release. "We've been working on a blood test since 1989", he said. "So I'm excited about that".
Findings of a new study indicate that disturbances in a person's sleep/wake cycle and internal body clocks may increase the risk of developing Alzheimer's disease.
The blood test identifies biological markers in blood plasma
Back then, researchers took blood samples from cognitively normal older people and compared them with samples from people with dementia to look for distinguishing markers.
One of the hallmarks of the disease is the accumulation of beta-amyloid plaques between nerve cells in the brain.
New research from the Washington University School of Medicine reveals that fragmented sleeping patterns in healthy adults could be an early warning sign of Alzheimer's Disease. "Maybe we had the blood test all along and didn't have the right gold standard". It is said to be 90% accurate.
But PETs are expensive. This could encourage more patients to enter clinical trials. In other words, they're only used on patients for whom treatment will be too little, too late.
Although a blood test is expected to be substantially cheaper than PET, the demand will still lag until there is a treatment available to benefit diagnosed patients, Dr. Yanagisawa said. "We hope our biomarker better facilitates clinical trials for [Alzheimer's] by improving enrollment of participants".
Although at an early stage, the success of the trial raises the possibility that Alzheimer's could be detected much earlier than is now possible - well before symptoms become apparent.
"This study reinforces the toxicity of oligomeric amyloid beta on neuronal mitochondria and stresses the importance for protective compounds to protect the mitochondria from oligomeric amyloid beta toxicity", Mastroeni said.